Wall Street analysts expect Endocyte, Inc. (NASDAQ:ECYT) to post earnings of ($0.35) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Endocyte’s earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.19). Endocyte posted earnings of ($0.21) per share in the same quarter last year, which suggests a negative year over year growth rate of 66.7%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Endocyte will report full year earnings of ($1.06) per share for the current year, with EPS estimates ranging from ($1.22) to ($0.89). For the next financial year, analysts expect that the business will report earnings of ($0.85) per share, with EPS estimates ranging from ($0.89) to ($0.80). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Endocyte.

Endocyte (NASDAQ:ECYT) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. The firm had revenue of $0.01 million for the quarter. During the same period in the prior year, the firm earned ($0.25) earnings per share.

A number of equities research analysts recently issued reports on the company. Cowen and Company reissued a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, October 3rd. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. Endocyte currently has a consensus rating of “Hold” and a consensus price target of $7.00.

Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its position in Endocyte by 1,064.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 393,975 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Endocyte by 34.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 25,003 shares in the last quarter. FMR LLC raised its position in Endocyte by 0.9% during the 2nd quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after purchasing an additional 31,168 shares in the last quarter. LMR Partners LLP bought a new stake in Endocyte during the 2nd quarter valued at $196,000. Finally, Spark Investment Management LLC bought a new stake in Endocyte during the 2nd quarter valued at $177,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/10/25/brokerages-anticipate-endocyte-inc-ecyt-will-announce-earnings-of-0-35-per-share.html.

Endocyte (NASDAQ:ECYT) opened at 4.535 on Wednesday. The firm’s market cap is $193.08 million. The firm’s 50 day moving average price is $3.08 and its 200-day moving average price is $2.14. Endocyte has a one year low of $1.17 and a one year high of $6.55.

Endocyte Company Profile

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.